Ischaemic ulcers on the toes secondary to Raynaud phenomenon in a patient with systemic sclerosis successfully treated with botulinum toxin

Garrido-Ríos, Anastasia Alejandra; González-Olivares, M.; Navarro-Vidal, Beatriz; Martínez‐Morán, C.; Borbujo, J.

doi:10.1111/ced.13333

Cited by 8 publications

(14 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although numerous publications demonstrated a positive effect of BoNT-A on RP [36][37][38][39][40], this review article will mainly focus on patients who had RP-associated ulcers. Based on the literature search, 12 articles (case reports, retrospective case series, and prospective case series) with a total of 104 patients who had RP-associated ulcers were identified (Table 1) [41][42][43][44][45][46][47][48][49][50][51][52]. Patients have been suffering from RP symptoms (pain, loss of function, disfigurement, and so forth) and chronic ischemic nonhealing ulcers.…”

Section: Ischemic Ulcers Secondary To Raynaud's Phenomenon (Rp)mentioning

confidence: 99%

“…Two reports from Korea used Medytoxin ® with the same dose of 10 units [48,52]. Other articles did not mention the type of BoNT-A or toxin brand with the dose of 32-100 units per 1 affected area [41,44,45,47,51]. In terms of reconstitution, most common reconstitution adopted was toxin 20 units to 0.9% NSS 1 mL [45,46,49,53].…”

Section: Bont-a For Various Types Of Skin Ulcers 41 Ischemic Ulcers S...mentioning

confidence: 99%

“…Other articles did not mention the type of BoNT-A or toxin brand with the dose of 32-100 units per 1 affected area [41,44,45,47,51]. In terms of reconstitution, most common reconstitution adopted was toxin 20 units to 0.9% NSS 1 mL [45,46,49,53]. Two reports from Korea used BoNT-A 100 units to 0.9% NSS 1 mL [48,52].…”

Section: Bont-a For Various Types Of Skin Ulcers 41 Ischemic Ulcers S...mentioning

confidence: 99%

“…Injection patterns are shown in Figure 2. There were two reports with foot ulcers injected at interdigital web space oriented toward the neurovascular bundle [44,45]. Parameters tracked outcomes consisted of objective and subjective measurements.…”

Section: Bont-a For Various Types Of Skin Ulcers 41 Ischemic Ulcers S...mentioning

confidence: 99%

See 3 more Smart Citations

Botulinum Toxin Type A for the Treatment of Skin Ulcers: A Review Article

Winayanuwattikun

Vachiramon

2022

Toxins

View full text Add to dashboard Cite

The normal biological wound healing process consists of three precisely and highly programmed phases that require optimal conditions including internal and external factors. Any negative factors that disrupt the sequence or time frame of the healing mechanism can result in a non-healing wound or chronic ulcers. Botulinum neurotoxin A (BoNT-A) which is generally known as anti-contraction of muscles has been reported as a successful treatment in various types of chronic ulcers. The aim of this study is to review the outcome of treatment with BoNT-A for chronic skin ulcers. The results demonstrated some positive effects of BoNT-A on chronic ulcers. Ischemic ulcers secondary to Raynaud’s phenomenon seem to be the most promising type of ulcers that have benefited from BoNT-A. The rationale behind using BoNT-A to fasten the wound healing process is also discussed. Further clinical trial studies should be conducted to affirm the efficacy of wound healing using BoNT-A administration.

show abstract

Section: Ischemic Ulcers Secondary To Raynaud's Phenomenon (Rp)mentioning

confidence: 99%

Section: Bont-a For Various Types Of Skin Ulcers 41 Ischemic Ulcers S...mentioning

confidence: 99%

Section: Bont-a For Various Types Of Skin Ulcers 41 Ischemic Ulcers S...mentioning

confidence: 99%

Section: Bont-a For Various Types Of Skin Ulcers 41 Ischemic Ulcers S...mentioning

confidence: 99%

See 2 more Smart Citations

Botulinum Toxin Type A for the Treatment of Skin Ulcers: A Review Article

Winayanuwattikun

Vachiramon

2022

Toxins

View full text Add to dashboard Cite

show abstract

“…This Digital Ulcer Clinical Assessment Score (DUCAS) has face and content validity and convergent/divergent correlations (construct validity) 26 . Besides well‐established EULAR for treating DU secondary to the RP, eyes are now geared towards the potential option of botulinum toxin 27,28 …”

Section: Skin Manifestations Of Sclerodermamentioning

confidence: 99%

The importance of skin manifestations, serology and nailfold (video)capillaroscopy in morphea and systemic sclerosis: current understanding and new insights

Mostmans

Richert

Badot

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Since the field around morphea and systemic sclerosis (SSc) is evolving rapidly, this review approaches conventional as well as more recent clinical developments from a dermatological point of view. Skin manifestations are critical in sub‐classifying these diseases ensuring a correct prognosis for these patients. They can be discretely present, and therefore, diagnosis can be challenging sometimes, implicating a thorough dermatological examination is mandatory. Furthermore, a growing amount of dermatologists perform nailfold videocapillaroscopy (NVC), a more recent reliable non‐invasive imaging technique used for in vivo assessment of the microcirculation at the nailfold. After all, specific NVC‐changes are present in a majority of patients with SSc. This way, dermatologists not only take part in the diagnosis process through clinical investigation but also through the use of a modern state of the art imaging technique that is becoming the golden standard in SSc multidisciplinary workup. In this review, current understandings for NVC in morphea and SSc are revised. So far, the role of NVC in the diagnosis/prognosis/classification of morphea patients has not been thoroughly investigated to make proper conclusions. As for SSc, it is well known that NVC contributes to the diagnosis and can make a fundamental difference especially when obvious clinical SSc signs are absent. This review emphasizes the (somewhat underestimated) role of dermatologists in the process of diagnosis and follow‐up, and thus, the difference we can make for our patients and fellow colleagues in the multidisciplinary workup of SSc and morphea.

show abstract